2005
Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV-Infected Individuals
Smith PF, DiCenzo R, Forrest A, Shelton M, Friedland G, Para M, Pollard R, Fischi M, DiFrancesco R, Morse GD. Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV-Infected Individuals. Clinical Pharmacokinetics 2005, 44: 99-109. PMID: 15634033, DOI: 10.2165/00003088-200544010-00004.Peer-Reviewed Original ResearchConceptsLarge interpatient variabilityPharmacokinetic parameter estimatesCombination regimensPopulation pharmacokineticsInterpatient variabilityNon-nucleoside reverse transcriptase inhibitorPopulation pharmacokinetic parameter estimatesCells/mm3Double-blind studyHIV-1 infectionMean apparent volumeAge 37 yearsPopulation pharmacokinetic analysisReverse transcriptase inhibitorVolume of distributionFirst-order clearanceTherapeutic drug monitoringTarget drug concentrationsCD4 countMonotherapy studiesOral clearanceDosage regimensPlasma concentrationsTranscriptase inhibitorPharmacokinetic analysis
1996
Stavudine (d4T, Zerit®)
Friedland G, Dunkle L, Cross A. Stavudine (d4T, Zerit®). Advances In Experimental Medicine And Biology 1996, 394: 271-277. PMID: 8815691, DOI: 10.1007/978-1-4757-9209-6_24.Peer-Reviewed Original ResearchConceptsAdvanced HIV-1 infectionEffects of stavudinePrior zidovudine therapyHIV-1 infectionImmunologic deteriorationAcceptable toxicityZidovudine therapyHIV diseaseClinical benefitSuch therapySurrogate markerClinical trialsDrug AdministrationStavudineTherapyBeneficial effectsU.S. FoodPatientsInfectionDiseaseAdministrationProgressionTrials
1994
Laboratory markers and the risk of developing HIV-1 disease among injecting drug users
Alcabes P, Selwyn P, Davenny K, Hartel D, Buono D, Schoenbaum E, Klein R, Friedland G. Laboratory markers and the risk of developing HIV-1 disease among injecting drug users. AIDS 1994, 8: 107-116. PMID: 7912083, DOI: 10.1097/00002030-199401000-00016.Peer-Reviewed Original ResearchConceptsCD4 lymphocyte countHIV-1-related outcomesLow CD4 lymphocyte countCD4 lymphocyte numbersPyogenic bacterial infectionsHIV-1 diseaseLymphocyte countLaboratory markersLymphocyte numbersClinical eventsAIDS diagnosisRelative riskDrug usersBacterial infectionsHIV-1-associated diseaseBeta 2M levelsSerum beta 2M levelsDifferent laboratory markersMultiple constitutional symptomsAIDS riskMethadone treatment programsPredictors of progressionHIV-1 infectionLow platelet countLower leukocyte counts